Early detection improves cancer survival rates. Autoantibodies can appear very early in disease, often long before onset of symptoms.
Read the white paper to learn:
Sengenics can help, with solutions to support discovery of biomarker signatures. Our high-density protein microarray assays enable highly specific and reproducible detection of disease-relevant autoantibodies directly from patient serum.
A Highly Predictive Autoantibody-based Biomarker Panel for Prognosis in Early-stage NSCLC with Potential Therapeutic Implications
Receiver Operating Characteristic (ROC) curves are commonly used in biological research to show the predictive value of a biomarker. Seen here are ROC curves for a novel autoantibody panel predictive of 5-year survival rates among non-small cell lung cancer patients. The blue line is from a training cohort and the green an independent validation cohort. The Area Under the Curve represents the predictive power of the panel. The p-value indicates no significant difference in the performance of this model between cohorts.
Taken from: Patel, A. J., et. al. (2022). A highly predictive autoantibody-based biomarker panel for prognosis in early-stage NSCLC with potential therapeutic implications. Br J Cancer, 126(2), 238-246. https://doi.org/10.1038/s41416-021-01572-x
